NIAID to Fund Pathogen, Toxin Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to provide $20 million in fiscal 2011 to fund its Partnerships for Biodefense program, which supports development of candidate diagnostics, therapeutics, vaccines, and adjuvants for pathogens and toxins that NIAID has labeled as Category A, B, or C priorities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.